Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues its relentless commitment to providing laboratories of all sizes with individualized and tailored support to meet the evolving list of regional and global compliance requirements.
Exploring PRM-A as a novel glycan-targeted therapy for SARS-CoV-2 inhibition
HIV, Ebola and most recently, COVID-19 viruses have had an enormous impact on our societies world-wide.